Journal of Neuroinflammation, scientists focused on triggering a receptor expressed on myeloid cell-2 (TREM2) to reduce or prevent the development of the amyloid plaques and neurofibrillary tangles.
They believe creating an antibody could activate the cell receptor an opposite action that occurs when a mutation suppress the cell resulting in Alzheimer’s.“TREM2 was identified several years ago as a gene that, when there’s a mutation, significantly increases risk of Alzheimer’s disease.
The field thinks that this mutation reduces the function of the receptor, so we hypothesized that targeting TREM2 to increase its function might be a valid treatment for Alzheimer’s,” explained Dr.
Read more on psychcentral.com